BRIEF published on 03/04/2024 at 08:05, 2 years 6 months ago Defence Therapeutics Gains Significant US Patent for Cancer-Killing AccuTOX® Technology Cancer Treatment Defence Therapeutics AccuTOX® Technology US Patent Antibody-drug Conjugates
PRESS RELEASE published on 03/04/2024 at 08:00, 2 years 6 months ago DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY Defence Therapeutics Inc. is granted a broad U.S. patent for its innovative cancer-killing AccuTOX technology, potentially providing market exclusivity until late 2042 Defence Therapeutics Inc. Broad U.S. Patent AccuTOX Technology Cancer-killing Market Exclusivity
PRESS RELEASE published on 11/07/2023 at 08:00, 2 years 10 months ago DEFENCE THERAPEUTICS KEY PLATFORM PATENT ACCEPTED BROADLY COVERING VACCINE TECHNOLOGY
PRESS RELEASE published on 10/25/2023 at 08:00, 2 years 10 months ago DEFENCE’S ACCUTOX® AND ANTIGEN CROSS-PRESENTATION: DISCOVERY LEADS TOWARDS THE DEVELOPMENT OF A GROUDNBREAKING PLATFORM
PRESS RELEASE published on 10/18/2023 at 08:00, 2 years 10 months ago Defence Therapeutics Inc.: DEFENCE’S NOVEL ACCUTOXTM CONTINUES TO SURPRISE ON RESULTS AGAINST CANCER
PRESS RELEASE published on 10/17/2023 at 08:00, 2 years 11 months ago Defence Therapeutics Inc.: DELIVERY OF ENCAPSULATED ACCUTOXTM-CHITOSAN NANOPARTICLES TRIGGERS COMPLETE TUMOR REGRESSION IN ANIMALS WITH PRE-ESTABSLIHED SOLID LYMPHOMA
PRESS RELEASE published on 10/10/2023 at 08:00, 2 years 11 months ago DEFENCE ANNOUNCES PEER-REVIEWED PUBLICATION OF ITS PRECLINICAL DATA ON ACCUM® AS AN ANTI-CANCER MOLECULE IN THE JOURNAL OF CANCER SCIENCE
PRESS RELEASE published on 09/25/2023 at 08:00, 2 years 11 months ago DEFENCE’S ACCUM®-mRNA LIPID NANOPARTICLES ELICIT ANTIBODY RESPONSE 2X STRONGER THAN STANDARD mRNA VACCINES
PRESS RELEASE published on 09/12/2023 at 08:00, 3 years ago DEFENCE’S BROAD AND VERSATILE ACCUM® TECHNOLOGY PLATFORM FOCUS ON CANCER THERAPEUTICS
PRESS RELEASE published on 09/05/2023 at 08:00, 3 years ago DEFENCE’S INNOVATIVE THERAPEUTICS FEATURED ON VIEWPOINT WITH DENNIS QUAID
Published on 09/18/2026 at 06:30, 1 hour 26 minutes ago GREE Chairperson Dong Mingzhu Honored by UNEP Cool Coalition for Leadership in Sustainable Cooling
Published on 09/18/2026 at 00:55, 7 hours 1 minute ago Tectonic Metals Announces Results of the 2026 Annual General Meeting
Published on 09/18/2026 at 00:25, 7 hours 31 minutes ago CoTec Holdings Corp. Announces Initial Closing of Private Placement of Unsecured Convertible Debentures
Published on 09/17/2026 at 22:15, 9 hours 41 minutes ago Rocky Shore Gold Announces Non-Brokered Private Placement
Published on 09/18/2026 at 07:15, 41 minutes ago Sandoz announces collaboration with mAbxience to expand patient access to life-enhancing biosimilar medicines
Published on 09/18/2026 at 07:00, 56 minutes ago Sandoz receives regulatory approval for generic semaglutide in Canada, paving way to expand patient access to key GLP-1 medicine
Published on 09/18/2026 at 06:45, 1 hour 11 minutes ago HUBER+SUHNER presents strategy and growth potential at Capital Market Day 2026
Published on 09/18/2026 at 05:30, 2 hours 26 minutes ago GREE Chairperson Dong Mingzhu Honored by UNEP Cool Coalition for Leadership in Sustainable Cooling
Published on 09/17/2026 at 19:00, 12 hours 56 minutes ago Max Verstappen Passes All 100 Karts in 14 Laps in Red Bull's Max vs 100
Published on 09/17/2026 at 17:40, 14 hours 16 minutes ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 17:45, 1 day 14 hours ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 2 days ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
